NCT01971814View on ClinicalTrials.gov

Early Serum Infliximab Levels in Severe Ulcerative Colitis.

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Ulcerative Colitis (UC)Inflammatory Bowel Disease
Interventions
DRUG

Infliximab

All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.

Trial Locations (1)

94143

University of California at San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT01971814 - Early Serum Infliximab Levels in Severe Ulcerative Colitis. | Biotech Hunter | Biotech Hunter